---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-017151"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T11:52:46.349512+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma FY2025 revenue $84.0M (+48% YoY); operating profit $19.6M (+81% YoY)

## Summary
- Consolidated revenue for FY2025 (ended March 31, 2025) was $84.0M, up 48% from $56.6M prior year.
- Operating profit rose 81% to $19.6M, driven by lisdexamfetamine products launched in FY2025 and Elite label product lines.
- Conference call scheduled for July 1, 2025 at 11:30 AM EDT to discuss results and business update.
- Company requests stockholder questions be submitted by 7:00 PM EDT on June 30, 2025.
- No EPS or net income figures disclosed in the press release; full 10-K filed separately.

## SEC filing metadata
- accession: 0001641172-25-017151
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000164117225017151/0001641172-25-017151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000164117225017151/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-017151
- JSON: https://secwatch.observer/filing/0001641172-25-017151.json
- Plain text: https://secwatch.observer/filing/0001641172-25-017151.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.